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background: Patients with diabetes (DM) are known to be at increased risk for cardiovascular (CV) events, but there are few data that describe 
current long term event rates in a real world population. We sought to evaluate the outcomes of patients with DM and identify predictors of CV 
events.
methods:The REACH Registry is an international, prospective cohort of patients with either established atherosclerosis or significant risk factors for 
atherosclerosis. Event rates at 4 years were determined using Kaplan Meier estimation for those with and without DM.
results: Of the 45,224 patients in the REACH registry with long term follow-up, 44% (n=19,699) had DM. The majority of patients with DM (70%) 
in the registry were from North America and Western Europe. In the cohort with established atherosclerosis, patients with DM had higher rates of CV 
Death, MI, or CVA compared to patients without DM (17.1% vs. 11.8%, p<0.001). In the cohort with risk factors and no established atherosclerosis, 
rates of CV Death, MI, or CVA were similar between patients with and without DM (8.1% vs. 7.3%, p=0.13) (Figure). Predictors of CV death, MI, 
or stroke in the patients with DM included polyvascular disease, CHF, prior MI/CVA, tobacco use, male sex, and increasing age. Statin usage was 
associated with lower risk of events.
conclusions: Patients with DM continue to have high rates of CV events, especially among those with established atherosclerosis. Novel therapies 
which reduce CV events in this high risk population are needed.
 
